Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MBII

Marrone Bio Innovations (MBII) Stock Price, News & Analysis

Marrone Bio Innovations logo

About Marrone Bio Innovations Stock (NASDAQ:MBII)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.80
$0.80
50-Day Range
$0.80
$0.80
52-Week Range
$0.55
$1.55
Volume
38 shs
Average Volume
919,497 shs
Market Capitalization
$145.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

Remove Ads

Marrone Bio Innovations Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
2nd Percentile Overall Score

MBII MarketRank™: 

Marrone Bio Innovations scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Marrone Bio Innovations.

  • Earnings Growth

    Earnings for Marrone Bio Innovations are expected to grow in the coming year, from ($0.06) to ($0.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Marrone Bio Innovations is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Marrone Bio Innovations is -6.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Marrone Bio Innovations has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for MBII.
  • Dividend Yield

    Marrone Bio Innovations does not currently pay a dividend.

  • Dividend Growth

    Marrone Bio Innovations does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MBII.
  • Search Interest

    1 people have searched for MBII on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Marrone Bio Innovations insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Marrone Bio Innovations is held by insiders.

  • Percentage Held by Institutions

    68.42% of the stock of Marrone Bio Innovations is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Marrone Bio Innovations' insider trading history.
Receive MBII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.

MBII Stock News Headlines

Upstream Bio Inc
Upstream Bio Inc (UPB)
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Man shot, killed by Olive Branch SWAT team
See More Headlines

MBII Stock Analysis - Frequently Asked Questions

Marrone Bio Innovations, Inc. (NASDAQ:MBII) issued its quarterly earnings data on Wednesday, November, 10th. The basic materials company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The basic materials company earned $9.86 million during the quarter, compared to analysts' expectations of $10.79 million. Marrone Bio Innovations had a negative net margin of 47.07% and a negative trailing twelve-month return on equity of 70.87%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Marrone Bio Innovations investors own include ObsEva (OBSV), Amyris (AMRS), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Rexahn Pharmaceuticals (REXN), Plug Power (PLUG) and Denali Therapeutics (DNLI).

Company Calendar

Last Earnings
11/10/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Agricultural Chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MBII
Fax
N/A
Employees
153
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,550,000.00
Pretax Margin
-47.12%

Debt

Sales & Book Value

Annual Sales
$44.31 million
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
4.69

Miscellaneous

Free Float
173,259,000
Market Cap
$145.56 million
Optionable
Not Optionable
Beta
0.36

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:MBII) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners